Executive Summary

Investment Thesis: Molina Healthcare reported a Q3 2026 beat and reaffirmed its full‑year adjusted outlook, and management presented preliminary 2027 earnings building blocks above $9.50 per share. Revenue of $11.08 billion modestly topped consensus, while GAAP and adjusted margins remain pressured as the company navigates Medicaid rate cycles and state contract ramps. Near-term upside appears limited based on the mean analyst target, yet upside catalysts tied to Medicaid rate realization and large contract implementations create a binary outcome for investors.

Current Price: $209.15 | Key Metric: Market Cap $10.92B | Stance: NEUTRAL

Company Overview

Molina Healthcare, Inc. (NYSE: $MOH) provides managed healthcare services primarily to low-income families and individuals through Medicaid and Medicare programs and health insurance marketplaces in the United States. The company operates through Medicaid, Medicare, Marketplace, and Other segments and serves enrollment-based, state-contracted populations.

Key Products & Competitive Position

Core Business: Managed care for Medicaid, Medicare Advantage, and ACA marketplace populations.
Key Products: Medicaid managed care plans, Medicare Advantage plans, Marketplace plans, behavioral health and long-term services coordination tied to state contracts.
Competitive Moat: Operational scale in state Medicaid programs, long-standing state relationships, and experience managing risk-based contracts for low-income populations.

Recent Developments

In Q3 2026 Molina beat consensus on both revenue and EPS, reaffirmed full-year adjusted earnings guidance, and presented preliminary building blocks for 2027 with adjusted EPS potential north of $9.50. Management commentary emphasized rate cycle progress in select states and the operational ramp for material contracts such as the Florida CMS work. Legal and implementation items tied to Georgia and Texas were flagged as items to watch.

Financial Snapshot

Market Cap$10.92B

P/E Ratio-342.87

52-Week Range$121.06 - $244.89

Dividend Yield0.0%

EPS (TTM)$-0.93

ROE-1.17%

Revenue & Earnings Trends

Q3 2026 revenue totaled $11.08 billion, a roughly 3.4% year over year decline, but ahead of the $10.87 billion consensus. GAAP income for the quarter was reported at $38 million, producing a thin profit margin near 0.34%. Adjusted EPS of $0.89 beat the $0.79 consensus and prior guidance. Trailing twelve‑month EPS is negative, reflecting prior periods of elevated costs and one‑time items, while management projects a sizable turnaround in adjusted earnings for 2027 if rate improvements and utilization trends evolve favorably.

Balance Sheet Highlights

Molina's current ratio sits around 1.69, indicating near‑term liquidity adequacy for operating needs. With a market cap near $10.9 billion and no widely reported balance sheet stress in the recent release, the focus shifts to working capital dynamics driven by state payment timing and medical cost trends. Return on equity is negative, reflecting the TTM loss position and past operating volatility.

Valuation Analysis

Current Valuation Metrics

Forward P/E~22.0vs Industry: ~18-20

PEG Ratio~2.20Growth-adjusted estimate

EV/EBITDA~10.0vs Historical: ~9-12

P/S Ratio0.99vs Peers: ~1.0-1.5

Historical Comparison

On a trailing basis, P/E is distorted by negative EPS. Using management's preliminary 2027 adjusted EPS building block above $9.50 produces a forward P/E in the low twenties, which is near or slightly above peer median depending on which peer set is used. P/S sits below 1.0 thanks to Molina's large revenue base, which reflects the low-margin nature of Medicaid products.

Fair Value Estimate

Combining the analyst mean target near $213.64 and a forward multiple anchored to projected adjusted EPS produces a mid‑$200s range for fair value under a scenario where 2027 adjusted earnings materialize as described. If management's building blocks miss meaningfully, fair value compresses toward the low‑$100s to high‑$100s range implied by the low analyst target.

Competitive Landscape

Market Position

Market Share: mid single‑digit share among Medicaid managed care enrollment nationwide | Ranking: a top 10 player in U.S. managed Medicaid

Key Competitors

UnitedHealth Group (UNH)UnitedHealth, diversified payer with extensive Medicaid and Medicare capabilities and broader scale advantages.

Elevance Health (ELV)Elevance Health, a major managed care operator with a strong Medicaid footprint and scale across products.

CVS Health (CVS)CVS Health, which competes through Aetna and integrated care capabilities including PBM and retail assets.

Competitive Advantages

Moat 1: Embedded state-level contracting relationships and operational experience in Medicaid delivery.
Moat 2: Scale in certain states that enables negotiating leverage with providers and administrative cost efficiencies.
Moat 3: Established care-management programs and data infrastructure for high‑need populations.

Earnings Track Record

Last 4 Quarters: 3 beats / 1 miss

Recent Earnings History

Q3 2026$0.89 vs $0.79 estBEAT

Q2 2026(mixed metrics vs est)BEAT/MIXED

Q1 2026(headwinds noted)MISS

Q4 2025(prior quarter beat)BEAT

Guidance Trend

Management reaffirmed full‑year 2026 adjusted earnings guidance and laid out preliminary 2027 building blocks implying adjusted EPS above $9.50. Analysts note the guidance is framework level rather than a formal confirmed number. The key sensitivity is the pace and durability of Medicaid rate increases that states implement over the coming quarters.

Analyst Sentiment

Consensus Rating: Hold

Strong Buy: 1 Buy: 3 Hold: 15 Sell: 0

Price Targets

Low: $129
Mean: $213.64 (+2.1% upside)
High: $286

Recent Analyst Actions

UBS maintained a Neutral rating on 10/23/2026 and raised its price target to $225 from $202. Other shops are holding or watching, reflected in the dominant Hold consensus. The narrow implied upside from the analyst mean signals limited immediate valuation cushion in aggregate.

Recent News & Catalysts

Key Developments

Q3 2026 Results: Reported Oct 21, 2026, revenue $11.08B and adjusted EPS $0.89, both ahead of consensus, while GAAP EPS was $0.73.
Guidance Framework: Management reaffirmed full‑year adjusted guidance and outlined 2027 building blocks implying adjusted EPS exceeding $9.50, driven by expected rate improvements and operational efficiencies.
Operational Ramps: Management highlighted the Florida CMS contract ramp and ongoing implementations in Georgia and Texas, along with related legal and implementation risk items to monitor.

Upcoming Catalysts

Next Earnings: Q4 FY2026 expected late Q1 2027 or Feb 2027, exact date TBD | Key Events: pace of Medicaid rate realizations, Florida contract operational updates, state payment timing, and legal outcomes in Georgia/Texas.

Technical Outlook

Current Price: $209.15 vs 52-Week High: $244.89 (-14.6% from high)

Trend Analysis

Technically, $MOH has pulled back from its 52‑week high but remains well above the 52‑week low. Volume on the most recent session was elevated versus the three‑month average, reflecting profit‑taking after the earnings week. The intermediate trend is range bound with sentiment hinging on clarity around 2027 execution.

Key Levels

Resistance: $220, $245
Support: $200, $180

Bull vs Bear Case

Bull Case

Catalyst 1: Medicaid rate cycles materialize faster than expected, lifting margins and producing durable adjusted earnings upside.
Catalyst 2: Smooth operational ramp of large state contracts such as Florida, improving scale economics and reducing implementation costs.
Catalyst 3: Current trading near analyst mean implies limited downside if management hits its 2027 building blocks, while upside remains if estimates are conservative.

Bull Target: $286 (+36.6%)

Bear Case

Risk 1: Delay or shortfall in Medicaid rate adjustments, keeping medical cost trends elevated versus premium and revenue inflections.
Risk 2: Implementation challenges or adverse legal outcomes in major state contracts, which could pressure near‑term cash flows.
Risk 3: Negative trailing EPS and prior margin volatility mean multiple compression if execution falters or utilization spikes.

Bear Target: $129 (-38.3%)

Risks to Consider

Valuation Risk: Trailing negative EPS and a P/E that is not meaningful complicate comparisons, and investor consensus pricing implies market sensitivity to execution; a miss could prompt sharp multiple contraction.
Competitive Risk: Large diversified payers have deeper scale and more diversified revenue streams, which can put pricing and network pressure on state Medicaid operators.
Macro Risk: State budget pressures, shifts in Medicaid eligibility, and changes to reimbursement or policy could materially alter expected rate trajectories.
Execution Risk: The timing and success of large contract implementations, including those in Florida, Georgia, and Texas, are binary variables that can swing near‑term performance.

Bottom Line

Investment Verdict: NEUTRAL

Molina Healthcare shows a mixed fundamental picture: a recent quarter that beat expectations and early 2027 earnings building blocks offer upside if realized, but the company still reports negative trailing EPS and thin margins that leave little margin for error. Analysts are largely in a Hold camp and the mean price target implies minimal upside heading into the long weekend. Can management turn the 2027 framework into consistent operating results and sustained margin improvement? That question will govern interest in the shares.

Action Items for Investors

Long-term investors: Monitor state rate implementation timelines, the Florida contract ramp, and 2027 adjusted earnings confirmation before reassessing exposure. Track quarterly medical cost trends relative to premium and rate actions.
Short-term traders: Watch earnings reaction to management remarks and legal/implementation headlines, and use clearly defined entry and exit levels around $200 and $220 to manage intraday or swing positions.
Risk management: Consider position sizing that reflects execution risk, and use stop limits or trailing rules if you need to limit downside from unexpected state or legal developments.

What to Watch This Week

Follow analyst notes and revisions after the company's Oct 21 Q3 release and the Oct 22 earnings call transcript.
State-level updates on Medicaid rate cycles, especially any concrete timing for payments or rate increases announced by major states.
Operational progress and legal updates on major contracts in Florida, Georgia, and Texas.

MOH: Q3 Beat, Medicaid Margins in Focus